Keywords: immunogen, gets, 5m, milestone, biopharmaceuticals, company, develops
ImmunoGen gets $5M milestone
Article | 06 August 2007
ImmunoGen, a US biopharmaceuticals company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, says that biotechnology major ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
